News Greenwich LifeSciences, Inc.

Equities

GLSI

US3968791083

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
12.62 ^USD	-3.96%		-3.30%	+19.96%

Apr. 15	Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Apr. 11	North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	DJ

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Greenwich LifeSciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 15	CI
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	Apr. 11	DJ
Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025	Mar. 13	AQ
Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe	Mar. 12	AQ
Greenwich Lifesciences Insider Bought Shares Worth $380,945, According to a Recent SEC Filing	Mar. 07	MT
Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries	Feb. 27	AQ
Greenwich LifeSciences Secures Approval to Expand GLSI-100's Phase 3 Trial to Europe	Feb. 22	MT
Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators	Feb. 22	AQ
Greenwich Lifesciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators	Feb. 22	CI
HC Wainwright Adjusts Greenwich LifeSciences Price Target to $36 From $38, Maintains Buy Rating	Feb. 20	MT
Greenwich LifeSciences, Inc. Provides Update on Phase III Clinical Trial, Flamingo-01	Feb. 14	CI
Sector Update: Health Care Stocks Rise in Afternoon Trading	Feb. 14	MT
Greenwich LifeSciences Shares Surge on Planned Regulatory Filing of Breast Cancer Treatment	Feb. 14	MT
Greenwich LifeSciences Shares Rise as Company Prepares FDA Filing for Breast Cancer Immunotherapy	Feb. 14	DJ
Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01	Feb. 14	AQ
Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024	Nov. 21	AQ
Greenwich LifeSciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-19	CI
North American Morning Briefing : Investors Await Powell's Jackson Hole Speech	23-08-25	DJ
Greenwich LifeSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-21	CI
Greenwich LifeSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Greenwich LifeSciences, Inc.

Equities

GLSI

US3968791083

Summary

Filters